---
title: "Apogee Therapeutics Executives Sell Shares"
date: "2025-02-08 09:10:00"
summary: "Reporter NameRelationshipTypeAmountSEC FilingHenderson Michael ThomasChief Executive OfficerSell$608,700Form 4Dambkowski CarlChief Medical OfficerSell$143,228Form 4Michael Thomas Henderson, Chief Executive Officer and Director at Apogee Therapeutics, sold 15,000 shares of Common Stock on February 5, 2025, at a weighted average price of $40.58 per share, totaling $608,700. Following the transaction, Henderson directly owns 1,302,987..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

| Reporter Name | Relationship | Type | Amount | SEC Filing |
| --- | --- | --- | --- | --- |
| Henderson Michael Thomas | Chief Executive Officer | Sell | $608,700 | [Form 4](https://www.sec.gov/Archives/edgar/data/1974640/000110465925010642/xslF345X05/tm255633-1_4seq1.xml) |
| Dambkowski Carl | Chief Medical Officer | Sell | $143,228 | [Form 4](https://www.sec.gov/Archives/edgar/data/1983476/000110465925010645/xslF345X05/tm255633-2_4seq1.xml) |

Michael Thomas Henderson, Chief Executive Officer and Director at Apogee Therapeutics, sold 15,000 shares of Common Stock on February 5, 2025, at a weighted average price of $40.58 per share, totaling $608,700. Following the transaction, Henderson directly owns 1,302,987 shares of the company. The sale was executed under a Rule 10b5-1 trading plan adopted on September 25, 2023.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold 3,520 shares of common stock on February 5, 2025, at a weighted average price of $40.69 per share, totaling $143,228. Following the transaction, Dambkowski directly owns 252,623 shares of the company.

[TradingView](https://www.tradingview.com/news/tradingview:23f31ed1148de:0-apogee-therapeutics-executives-sell-shares/)
